Volver a ensayos

Pan-Tumor Study for Long-term Treatment of Cancer Patients Who Have Participated in BMS Sponsored Trials Investigating Nivolumab and Other Cancer Therapies

ReclutandoFase 2ClinicalTrials.gov

ID: NCT03899155Tipo: INTERVENTIONALInicio: 5 de may de 2020Fin estimado: 25 de ago de 2029

Oncología Neurología

Traducción no disponible, mostrando original

Resumen

Main Objective of this study is to examine long-term safety of nivolumab monotherapy including combinations and other cancer therapies in various tumor types.

Elegibilidad

Edad mínima: 18 YearsSexo: ALL

Criterios de inclusión

Signed Written Informed Consent.
Eligible to receive continued study treatment per the Parent Study, including treatment beyond progression per investigator assessment in the Parent Study.
On treatment hold in the Parent Study following long-lasting response or are eligible for treatment rechallenge as defined in the Parent Study.
WOCBP and male participants who are sexually active must agree to follow instructions for method(s) of contraception as described below and included in the ICF.

Criterios de exclusión

Participant is not eligible for study treatment per the Parent Study eligibility criteria.
Participants not receiving clinical benefit as assessed by the Investigator.
Any clinical adverse event (AE), laboratory abnormality, or intercurrent illness which, in the opinion of the Investigator, indicates that participation in the study is not in the best interest of the participant.

Intervenciones

drug

Nivolumab

Specified dose on specified days

drug

Ipilimumab

Specified dose on specified days

drug

Cabozantinib

Specified dose on specified days

drug

Trametinib

Specified dose on specified days

drug

Relatlimab

Specified dose on specified days

drug

Nivolumab + Relatlimab

Specified dose on specified days

drug

Capecitabine

Specified dose on specified days

drug

Bevacizumab

Specified dose on specified days

drug

Temozolomide

Specified dose on specified days

drug

Rucaparib

Specified dose on specified days

drug

Daratumumab

Specified dose on specified days

drug

Regorafinib

Specified dose on specified days

drug

Leucovorin

Specified dose on specified days

drug

Fluorouracil

Specified dose on specified days

drug

Oxaliplatin

Specified dose on specified days

drug

Enzalutamide

Specified dose on specified days

drug

Sunitinib

Specified dose on specified days

drug

Pemetrexed

Specified dose on specified days

drug

Pembrolizumab

Specified dose on specified days

Ubicaciones

Local Institution - 0199

Berazategui, Buenos Aires, Argentina

COMPLETED

Instituto Medico Rio Cuarto

Río Cuarto, Córdoba Province, Argentina

Alejo Lingua, Site 0415 · 54351153819050

RECRUITING

Centro de Investigaciones Clinicas. Clinica Viedma S.A.

Viedma, Río Negro Province, Argentina

Ruben Kowalyszyn, Site 0405 · 5492920601693

RECRUITING

Sanatorio Parque

Rosario, Santa Fe Province, Argentina

Gaston Lucas Martinengo, Site 0407

RECRUITING

CAIPO Centro para la Atencion Integral del Paciente Oncologico

San Miguel de Tucumán, Tucumán Province, Argentina

Felipe Salvador Palazzo, Site 0376 · 543814018300

RECRUITING

Local Institution - 0191

San Miguel de Tucumán, Tucumán Province, Argentina

COMPLETED

Local Institution - 0201

Buenos Aires, Argentina

WITHDRAWN

Instituto Fleming

Buenos Aires, Argentina

Matias Chacon, Site 0030 · +541138850425

RECRUITING

Local Institution

CABA, Argentina

WITHDRAWN

Fundacion Richardet Longo - IONC

Córdoba, Argentina

Martin Richardet, Site 0349 · 5493516165267

RECRUITING

Local Institution - 0170

Córdoba, Argentina

WITHDRAWN

Patrocinadores

PrincipalBristol-Myers Squibb

ColaboradorExelixis

ColaboradorNovartis

ColaboradorClovis Oncology, Inc.

ColaboradorJanssen Pharmaceuticals

Contactos

BMS Clinical Trials Contact Center www.BMSClinicalTrials.com

CONTACT

Clinical.Trials@bms.com 855-907-3286

First line of the email MUST contain NCT # and Site #.

CONTACT

Aviso: La información de este ensayo proviene de fuentes públicas y tiene carácter exclusivamente informativo. No constituye asesoramiento médico, regulatorio ni de ningún otro tipo. Las traducciones son automatizadas y no poseen validez oficial. Consultá siempre con un profesional de la salud. Ver Términos de Uso.

Pan-Tumor Study for Long-term Treatment of Cancer Patient... | EligiMed